In the same study, Steigerwald et al. demonstrated that LLP3 might also be effective as monotherapy in the subgroup of p53-proficient and some p53-mutated tumors in CRC, independent of mismatch repair status [149]. Here, TP53 is linked to colorectal carcinoma.